{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:32:40Z","timestamp":1790310760235,"version":"4.1.0"},"reference-count":72,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched PubMed\/Embase\/ClinicalTrials.gov. Prevalence of each racial\/ethnic group was compared in relation to the USA, Canada, the UK, Brazil and South Africa. The geographical locations of the trial sites were extracted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>27 RCTs were identified (n=21 547 participants). Meta-analyses of prevalence demonstrated the vast predominance of white\/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%). The gaps in representation were evidenced by the significantly under-represented proportion of non-white individuals in these RCTs as compared with the prevalence of non-white individuals in the general population of the USA (\u221223%, p=0.002) and Canada (\u221234%, p&lt;0.0001), reaching an alarming gap of \u221258% in relation to Brazil and striking under-representation of \u221268% as compared with South Africa. Similar discrepancies in proportions of blacks, Asians and Indigenous peoples as compared with reference nations were found. Moreover, the trial sites (n=1859) were predominately located in high-income countries (84.2%), in sharp contrast to the global prevalence of obesity that is predominantly in low-income and middle-income countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There are discrepancies in representation of racialised and ethnically diverse populations in obesity trials as compared with multiethnic populations worldwide. These data highlight the need for broader reform in the research process in order to ultimately address health inequities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-017177","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:21:21Z","timestamp":1732767681000},"page":"e017177","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps"],"prefix":"10.1136","volume":"9","author":[{"given":"Yaanu","family":"Jeyakumar","sequence":"first","affiliation":[{"name":"Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Richardson","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohinee","family":"Sarma","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Retnakaran","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-0100","authenticated-orcid":false,"given":"Caroline K","family":"Kramer","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2025073013592838000_9.11.e017177.1","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) . Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024;4031027\u201350."},{"key":"2025073013592838000_9.11.e017177.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000367"},{"key":"2025073013592838000_9.11.e017177.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-11-201312030-00008"},{"key":"2025073013592838000_9.11.e017177.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"2025073013592838000_9.11.e017177.5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41366-023-01332-2","article-title":"Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish Obese Subjects","volume":"47","author":"Carlsson","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"2025073013592838000_9.11.e017177.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00271-3"},{"key":"2025073013592838000_9.11.e017177.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01640-8"},{"key":"2025073013592838000_9.11.e017177.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2025073013592838000_9.11.e017177.9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2025073013592838000_9.11.e017177.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"2025073013592838000_9.11.e017177.11","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025073013592838000_9.11.e017177.12","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"key":"2025073013592838000_9.11.e017177.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"2025073013592838000_9.11.e017177.14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2025073013592838000_9.11.e017177.15","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/S0140-6736(22)00625-0","article-title":"The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry","volume":"400","author":"Kramer","year":"2022","journal-title":"Lancet"},{"key":"2025073013592838000_9.11.e017177.16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071923","article-title":"Race, Ethnicity, and Pharmacogenomic Variation in the United States and the United Kingdom","volume":"15","author":"Sharma","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025073013592838000_9.11.e017177.17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2213-8587(21)00088-7","article-title":"Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study","volume":"9","author":"Caleyachetty","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2215609"},{"key":"2025073013592838000_9.11.e017177.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025073013592838000_9.11.e017177.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025073013592838000_9.11.e017177.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025073013592838000_9.11.e017177.22","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025073013592838000_9.11.e017177.23","unstructured":"Census USA. Available: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045221 [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.24","unstructured":"Census Canada. Available: https:\/\/www12.statcan.gc.ca\/census-recensement\/index-eng.cfm [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.25","unstructured":"Census UK. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/culturalidentity\/ethnicity\/bulletins\/ethnicgroupenglandandwales\/census2021 [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.26","unstructured":"Census Brazil. Available: https:\/\/censo2022.ibge.gov.br\/panorama [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.27","unstructured":"Census South Africa. Available: https:\/\/www.gov.za\/about-sa\/south-africas-people [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.28","unstructured":"World bank income groups. Available: https:\/\/datatopics.worldbank.org\/world-development-indicators\/the-world-by-income-and-region.html [Accessed 22 May 2024]."},{"key":"2025073013592838000_9.11.e017177.29","unstructured":"World Obesity Federation . World obesity Atlas 2024. London World Obesity Federation; 2024. Available: https:\/\/data.worldobesity.org\/publications\/?cat=22"},{"key":"2025073013592838000_9.11.e017177.30","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"2025073013592838000_9.11.e017177.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"2025073013592838000_9.11.e017177.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"2025073013592838000_9.11.e017177.33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"2025073013592838000_9.11.e017177.34","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745"},{"key":"2025073013592838000_9.11.e017177.35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"2025073013592838000_9.11.e017177.36","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"2025073013592838000_9.11.e017177.37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0"},{"key":"2025073013592838000_9.11.e017177.38","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151"},{"key":"2025073013592838000_9.11.e017177.39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"2025073013592838000_9.11.e017177.40","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.1831"},{"key":"2025073013592838000_9.11.e017177.41","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-02026-4"},{"key":"2025073013592838000_9.11.e017177.42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"2025073013592838000_9.11.e017177.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"2025073013592838000_9.11.e017177.45","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"TEP-HFpEF DM Trial Committees and Investigators. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025073013592838000_9.11.e017177.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"2025073013592838000_9.11.e017177.47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"2025073013592838000_9.11.e017177.48","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2025073013592838000_9.11.e017177.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392"},{"key":"2025073013592838000_9.11.e017177.50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"2025073013592838000_9.11.e017177.51","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025073013592838000_9.11.e017177.52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.54","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.140"},{"key":"2025073013592838000_9.11.e017177.55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-8587(24)00098-6","article-title":"Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review","volume":"12","author":"Alsaqaaby","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13749","article-title":"Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020","volume":"4","author":"Steinberg","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025073013592838000_9.11.e017177.57","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00404-023-07367-0","article-title":"Obesity management: sex-specific considerations","volume":"309","author":"Kantowski","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"2025073013592838000_9.11.e017177.58","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14631","article-title":"Association of Sex or Race With the Effect of Weight Loss on Physical Function: A Secondary Analysis of 8 Randomized Clinical Trials","volume":"3","author":"Beavers","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025073013592838000_9.11.e017177.59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13300-022-01360-7","article-title":"Semaglutide in Obesity: Unmet Needs in Men","volume":"14","author":"Jensterle","year":"2023","journal-title":"Diabetes Ther"},{"key":"2025073013592838000_9.11.e017177.60","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2025073013592838000_9.11.e017177.61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuropharm.2016.07.039","article-title":"GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight","volume":"110","author":"Vogel","year":"2016","journal-title":"Neuropharmacology"},{"key":"2025073013592838000_9.11.e017177.62","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1007\/s40615-022-01487-0","article-title":"A Systematic Review on Participant Diversity in Clinical Trials-Have We Made Progress for the Management of Obesity and Its Metabolic Sequelae in Diet, Drug, and Surgical Trials","volume":"10","author":"Johnson-Mann","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"2025073013592838000_9.11.e017177.63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/dom.12632","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials","volume":"18","author":"Ard","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025073013592838000_9.11.e017177.64","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"2025073013592838000_9.11.e017177.65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(15)00080-7","article-title":"Country in Focus: health disparities in Indigenous Canadians","volume":"3","author":"Pirisi","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073013592838000_9.11.e017177.66","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028409","article-title":"Racial Disparities in Obesity-Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020","volume":"12","author":"Raisi-Estabragh","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025073013592838000_9.11.e017177.67","unstructured":"Mukhwana A , Shorinola O , Ndlovu D . Slow, difficult and expensive: how the lab supplies market is crippling african science. n.d. Available: https:\/\/www.nature.com\/nature-index\/news\/slow-difficult-expensive-how-lab-supplies-market-crippling-african-science"},{"key":"2025073013592838000_9.11.e017177.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371209"},{"key":"2025073013592838000_9.11.e017177.69","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302779"},{"key":"2025073013592838000_9.11.e017177.70","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170448"},{"key":"2025073013592838000_9.11.e017177.71","doi-asserted-by":"crossref","first-page":"e1383","DOI":"10.1016\/S2214-109X(22)00356-4","article-title":"One hundred years of solitude-underrepresentation of Indigenous and minority groups in diabetes trials","volume":"10","author":"Sarma","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2025073013592838000_9.11.e017177.72","unstructured":"Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research . Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC): National Academies Press (US), 2022."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-017177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:59:41Z","timestamp":1753909181000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-017177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":72,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,28]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjgh-2024-017177"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-017177","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}